Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT07491172
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:09.279571+00:00
Published At
2026-03-24T00:00:00+00:00
Record Updated At
2026-03-24
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Cardiovascular", "Metabolic Disease", "Dyslipidemias", "Lipid Disorder", "Hypertriglyceridemia", "Heterozygous Familial Hypercholesterolemia (HeFH)", "Homozygous Familial Hypercholesterolemia (HoFH)", "Severe Hypertriglyceridemia (sHTG)", "Mixed Hyperlipemia", "Hypercholesterolaemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-03-24"
protocolSection.identificationModule.nctId
"NCT07491172"
protocolSection.identificationModule.officialTitle
"A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Cardiovascular (protocolSection.conditionsModule.conditions)
  • Metabolic Disease (protocolSection.conditionsModule.conditions)
  • Dyslipidemias (protocolSection.conditionsModule.conditions)
  • Lipid Disorder (protocolSection.conditionsModule.conditions)
  • Hypertriglyceridemia (protocolSection.conditionsModule.conditions)
  • Heterozygous Familial Hypercholesterolemia (HeFH) (protocolSection.conditionsModule.conditions)
  • Homozygous Familial Hypercholesterolemia (HoFH) (protocolSection.conditionsModule.conditions)
  • Severe Hypertriglyceridemia (sHTG) (protocolSection.conditionsModule.conditions)
  • Mixed Hyperlipemia (protocolSection.conditionsModule.conditions)
  • Hypercholesterolaemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.